Illumina (ILMN)
(Delayed Data from NSDQ)
$117.93 USD
-6.06 (-4.89%)
Updated May 3, 2024 04:00 PM ET
After-Market: $117.85 -0.08 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Brokerage Reports
0 items in cart
Illumina, Inc. [ILMN]
Reports for Purchase
Showing records 321 - 340 ( 360 total )
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
4Q11 Results Review: Good End to 2011; Guidance for 2012 Looks Solid; Rejects Roche''s Offer as "Inadequate"
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
4Q11 Recap - Strong Sequencing Rebound - Genotyping Light But Orders Encouraging
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Roche Goes Hostile - Offers $44.50 per Share for ILMN: Likely Only an Opening Offer
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Roche Initiates Hostile Bid for $44.50 - Not Enough Given Recent Progress & FCF Yield - Raising Estimates & PT from $35 to $50
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Maintaining LT OUTPERFORM But Less Optimistic on GMs Due To Higher Trade-In Discounting Data Point; MiSeq Delivery Delays Difficult To Interpret
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
3Q11 Results Roughly In-line - Solid GMs and Cash Flow - Increasing Backlog - Sample Access Issue Still Murky - Maintaining OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
3Q11 Preview - Sequencer Utilization & Operating Leverage Under Scrutiny
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Lowering PT to $35 from $78 After Big 3Q11 Whiff on Budget-Driven Sequencing Slowdown
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Ugly 3Q Preannouncement as Funding Environment Weighs; Reducing Estimates and Target
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Maintaining OUTPERFORM Thesis Following Wedbush Life Science Tools Bus Tour
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
2Q11 Results Review: Great Quarter and Solid Guidance Run Head on Into Even Greater Expectations
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Reaffirming OUTPERFORM- Buyers on the Selloff-PT Down a Smidgen to $78
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Reaffirming OUTPERFORM Rating Ahead of 2Q11 Earnings
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
1Q11 Results Review-We are assuming coverage with a Buy rating and a $75 price
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Rock Solid 1Q11 Beats on Strong Systems & Consumables; Likely To Be More Where That Came From; Raising PT to $80 from $75
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
1Q11 Financial Preview; Instrument Placements Likely Good; Possible Play on 2007 Utilization Redux; Improving Psychology Too
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Pullback Creates Opportunity to Own NGS Leader - Upgrading to Buy and Reiterating $75 PT
Provider: AURIGA USA
Analyst: MEHRA R